Literature DB >> 35247983

Age is the main determinant of COVID-19 related in-hospital mortality with minimal impact of pre-existing comorbidities, a retrospective cohort study.

M T H M Henkens1,2, A G Raafs3, F W Asselbergs4,5,6, F J H Magdelijns7, J A J Verdonschot8, M Linschoten4, M van Smeden9, P Wang8, B H M van der Hooft7, R Tieleman10, M L F Janssen11, R M A Ter Bekke3, M R Hazebroek3, I C C van der Horst3,12, S R B Heymans3,13,14.   

Abstract

BACKGROUND: Age and comorbidities increase COVID-19 related in-hospital mortality risk, but the extent by which comorbidities mediate the impact of age remains unknown.
METHODS: In this multicenter retrospective cohort study with data from 45 Dutch hospitals, 4806 proven COVID-19 patients hospitalized in Dutch hospitals (between February and July 2020) from the CAPACITY-COVID registry were included (age 69[58-77]years, 64% men). The primary outcome was defined as a combination of in-hospital mortality or discharge with palliative care. Logistic regression analysis was performed to analyze the associations between sex, age, and comorbidities with the primary outcome. The effect of comorbidities on the relation of age with the primary outcome was evaluated using mediation analysis.
RESULTS: In-hospital COVID-19 related mortality occurred in 1108 (23%) patients, 836 (76%) were aged ≥70 years (70+). Both age 70+ and female sex were univariably associated with outcome (odds ratio [OR]4.68, 95%confidence interval [4.02-5.45], OR0.68[0.59-0.79], respectively;both p<  0.001). All comorbidities were univariably associated with outcome (p<0.001), and all but dyslipidemia remained significant after adjustment for age70+ and sex. The impact of comorbidities was attenuated after age-spline adjustment, only leaving female sex, diabetes mellitus (DM), chronic kidney disease (CKD), and chronic pulmonary obstructive disease (COPD) significantly associated (female OR0.65[0.55-0.75], DM OR1.47[1.26-1.72], CKD OR1.61[1.32-1.97], COPD OR1.30[1.07-1.59]). Pre-existing comorbidities in older patients negligibly (<6% in all comorbidities) mediated the association between higher age and outcome.
CONCLUSIONS: Age is the main determinant of COVID-19 related in-hospital mortality, with negligible mediation effect of pre-existing comorbidities. TRIAL REGISTRATION: CAPACITY-COVID ( NCT04325412 ).
© 2022. The Author(s).

Entities:  

Keywords:  COVID-19; Hospitalization; Mediation analysis; Mortality; Netherlands

Mesh:

Year:  2022        PMID: 35247983      PMCID: PMC8897728          DOI: 10.1186/s12877-021-02673-1

Source DB:  PubMed          Journal:  BMC Geriatr        ISSN: 1471-2318            Impact factor:   3.921


Background

COVID-19 is a pandemic infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-19), which already accounts for over 5 million deaths worldwide [1]. COVID-19 related mortality is particularly high in the elderly [2-6]. Consequently, in the Netherlands, 90% of the deceased patients is 70 years or older [7]. Pre-existing comorbidities such as hypertension, diabetes mellitus (DM), dyslipidemia, chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), and history of cardiac diseases are also associated with an increased risk of COVID-19 related (in-hospital) mortality [8-12]. However, these comorbidities are also known to be more prevalent in the elderly [8, 9, 13]. It remains unknown to which extent the higher in-hospital mortality rate is mediated by the higher prevalence of these comorbidities in the elderly. The aim of this study was to explore to which extent existing comorbidities mediate the increased risk of COVID-19 related in-hospital mortality relative to age in a registry of 4806 Dutch COVID-19 patients.

Methods

Study design and population

CAPACITY-COVID (NCT04325412) is an international patient registry established to investigate the role of cardiovascular disease in the COVID-19 pandemic [14, 15]. The details of this registry have been outlined in detail previously [15]. In short, adult patients (≥18 years) with (highly suspected) COVID-19 admitted to one of the participating hospitals were included in this registry [14]. Forty-five Dutch hospitals contributed to the registry. For the current analysis, consecutive patients from all participating Dutch hospitals with proven COVID-19 infection based on at least one positive PCR for SARS-CoV-2 (92% of the included subjects) and/or a chest CT scan strongly suggestive for SARS-CoV-2 infection, hospitalized between January and July 2020 (first COVID-19 wave in the Netherlands), were included [14-16]. In-hospital mortality was defined as a combination of in-hospital mortality or discharge with palliative care. The study was performed according to the Helsinki declaration and local ethics approval was obtained in all participating hospitals. Consent was obtained by either opt-in (when required by the local Medical Research Ethics Committee of the participating center) or opt-out approaches, following local regulations.

Statistical analyses

Variables are displayed as numbers (percentage), mean ± standard deviation (SD) or median and inter quartile ranges [IQR], as appropriate. Normality was assessed visually using Q-Q plots. Comparisons between groups were performed using chi-square tests for categorical data and for continuous variables by independent sample T-test or Mann Whitney-U test depending on normality of the distribution. Unadjusted binary logistic regression analysis was performed to analyze the associations between sex, age 60+, age 70+, a reported medical history of comorbidities (hypertension, DM, dyslipidemia, CKD, COPD, and a medical history of cardiac disease) and the comorbidity count (a sum of the presence of the before mentioned comorbidities categorized as 0 co-morbidities, 1–2 co-morbidities, and > 2 co-morbidities) with in-hospital mortality. Definitions of pre-existing comorbidities as specified in the case report form are provided in the Supplemental Methods (Additional file 1). Subsequently, adjusted binary logistic regression analysis – with adjustment for age 70+ and sex – was performed to determine the adjusted association between comorbidities and the comorbidity count with in-hospital mortality. Additionally, given the non-linear relationship between age and in-hospital mortality, age-restricted cubic spline adjusted logistic regression models were constructed for sex and the comorbidities [17]. R mediation package 4.5.0 was used to perform the mediation analysis [18]. The mediation analysis tests whether a clinical variable (in this case age 70+) affects outcome through a mediator variable (in this case the co-morbidities) and to which extent. This divides the total effect of the model into a direct effect, called the average direct effect (ADE), and an indirect effect, called the average causal mediation effect (ACME). The proportion of ADE and ACME and the 95% confidence intervals (using 1000x bootstrapping) were calculated and visualized for each comorbidity studied. Statistical analyses were conducted in R, and figures were made using the packages ggplot2 and forest plot [19-21]. Statistical significance was defined as a P value < 0.05.

Results

Patient characteristics

In total, 4806 patients fulfilled the inclusion criteria and were included in this study. Clinical characteristics stratified by age < 70 and ≥ 70 years are outlined in Table 1. The median age was 69 [58-77] years, and approximately two-third were men (63%, N = 3051). All pre-existing comorbidities were more prevalent in the elderly (aged ≥70 years, all p < 0.001). Male patients more often had dyslipidemia (46% vs 39%), a history of cardiac disease (39% vs 30%, especially coronary artery disease and arrhythmias) and presence of two or more comorbidities when compared to women (39% vs 33%, Additional file 2).
Table 1

Clinical characteristics of patients aged < 70 and aged ≥70 (70+) years

< 70(N = 2504)70+(N = 2302)Total(N = 4806)P-value
Clinical Presentation
 Age, years58 [51–64]77 [73–82]69 [58–77]< 0.001
 Female910 (36%)845 (37%)1755 (37%)0.793
 BMI, kg/m227.9 [25.1–31.2]26.7 [24.0–30.1]27.3 [24.5–30.8]<  0.001
 Temperature, °C37.9 ± 1.137.7 ± 1.137.8 ± 1.1<  0.001
 Heart rate, bpm91 [80–103]86 [75–99]89 [77–101]<  0.001
 Systolic BP, mmHg133 ± 21136 ± 24135 ± 23<  0.001
 Diastolic BP, mmHg78 ± 1475 ± 1577 ± 15<  0.001
 Breathing rate, rpm22 [18–26]21 [18–26]22 [18–26]0.620
 Oxygen saturation, So2%95 [92–97]95 [92–96]95 [92–97]<  0.001
Medical History, n (%)
 Hypertension1036 (41%)1720 (75%)2756 (57%)<  0.001
 Diabetes Mellitus512 (20%)701 (31%)1213 (25%)<  0.001
 Dyslipidemia764 (31%)1303 (57%)2067 (43%)<  0.001
 Chronic Kidney Disease127 (5%)392 (17%)519 (11%)<  0.001
 COPD206 (8%)373 (16%)579 (12%)<  0.001
 Cardiac disease488 (20%)1218 (53%)1706 (36%)<  0.001
  Arrhyth./Conduc.160 (6%)612 (27%)772 (16%)< 0.001
  Heart Failure46 (2%)228 (10%)274 (6%)< 0.001
  Coronary Artery Disease249 (10%)574 (25%)823 (17%)< 0.001
  Valvular Heart Disease50 (2%)201 (9%)251 (5%)< 0.001
 Comorbidity count< 0.001
  0 comorbidities1073 (43%)250 (11%)1323 (28%)
  1–2 comorbidities896 (36%)842 (37%)1738 (36%)
   > 2 comorbidities535 (21%)1210 (53%)1745 (36%)

Arrhyth arrhythmias, BMI body mass index, BP blood pressure, Conduc conduction disorders, COPD chronic obstructive pulmonary disease

Clinical characteristics of patients aged < 70 and aged ≥70 (70+) years Arrhyth arrhythmias, BMI body mass index, BP blood pressure, Conduc conduction disorders, COPD chronic obstructive pulmonary disease Median duration of hospitalization was 7 [4 - 15] days. In-hospital mortality (N  = 1066, 96%) or palliative discharge (N = 42, 4%) occurred in 1108 (23%) patients, of which 836 (76%) were aged 70+ and 272 (24%) were aged < 70 (p <  0.001; Table 2). The observed and predicted association between age (splined adjusted) and in-hospital mortality are shown in Fig. 1. Male sex and the individual comorbidities were more prevalent, and comorbidity count per patient was higher in the in-hospital mortality group (p < 0.001, Table 2). In total, 1312 (27%) patients were referred to the intensive care unit (ICU) during hospitalization, of which 446 were aged 70+ (34%) and 866 (66%) were aged < 70 (p < 0.001).
Table 2

Clinical characteristics of patients with and without event

No mortality or Palliative Care(N = 3698)Mortality or Palliative Care(N = 1108)Total(N = 4806)P-value
Clinical Presentation
 Age, years65 [56–74]76 [70–82]69 [58–77]< 0.001
 Female1423 (39%)332 (30%)1755 (37%)< 0.001
 BMI, kgm−227.5 [24.7–30.8]26.8 [24.1–30.5]27.3 [24.5–30.8]0.010
 Temperature, °C37.8 ± 1.137.8 ± 1.137.8 ± 1.10.454
 Heart rate, bpm89 [78–100]90 [77–103]89 [77–101]0.087
 Systolic BP, mmHg135 ± 22134 ± 25135 ± 230.301
 Diastolic BP, mmHg77 ± 1473 ± 1677 ± 15< 0.001
 Breathing rate, rpm20 [17–25]24 [19–28]22 [18–26]< 0.001
 Oxygen saturation, So2%95 [93–97]94 [91–96]95 [92–97]< 0.001
Medical History
 Hypertension1979 (54%)777 (70%)2756 (57%)< 0.001
 Diabetes Mellitus835 (23%)378 (34%)1213 (25%)< 0.001
 Dyslipidemia1479 (40%)588 (53%)2067 (43%)< 0.001
 Chronic Kidney Disease311 (8%)208 (19%)519 (11%)< 0.001
 COPD389 (11%)190 (17%)579 (12%)< 0.001
 Cardiac disease1170 (32%)536 (48%)1706 (36%)< 0.001
  Arrhyth./Conduc.509 (14%)263 (24%)772 (16%)< 0.001
  Heart Failure168 (5%)106 (10%)274 (6%)< 0.001
  Coronary Artery Disease540 (15%)283 (26%)823 (17%)< 0.001
  Valvular Heart Disease155 (4%)96 (9%)251 (5%)< 0.001
Comorbidity count< 0.001
  0 comorbidities1164 (32%)159 (14%)1323 (28%)
  1–2 comorbidities1354 (37%)384 (35%)1738 (36%)
   > 2 comorbidities1180 (32%)565 (51%)1745 (36%)

Arrhyth arrhythmias, BMI body mass index, BP blood pressure, Conduc conduction disorders, COPD chronic obstructive pulmonary disease

Fig. 1

Predicted and observed in-hospital mortality (univariable age-restricted cubic spline adjusted). % Mortality predicted: The white line represents the predicted mortality rates at different ages, accompanied by 95% confidence intervals in blue. # Observed patients: The grey bars represent the number of patients observed within the different age categories. The light grey bars are the patients that were discharged without palliative care. The dark grey bars are the patients in which in-hospital mortality (or palliative discharge) occurred

Clinical characteristics of patients with and without event Arrhyth arrhythmias, BMI body mass index, BP blood pressure, Conduc conduction disorders, COPD chronic obstructive pulmonary disease Predicted and observed in-hospital mortality (univariable age-restricted cubic spline adjusted). % Mortality predicted: The white line represents the predicted mortality rates at different ages, accompanied by 95% confidence intervals in blue. # Observed patients: The grey bars represent the number of patients observed within the different age categories. The light grey bars are the patients that were discharged without palliative care. The dark grey bars are the patients in which in-hospital mortality (or palliative discharge) occurred

Univariable and multivariable associations and mediation effect of comorbidities and in-hospital mortality

Higher age (70+), male sex, and the individual comorbidities were all significantly associated with in-hospital mortality in univariable analysis (all p < 0.001; Fig. 2A). Hypertension, DM, CKD, COPD and a history of cardiac disease remained significantly associated after adjustment for age 70+ and sex (hypertension odds ratio [OR] 1.29, 95% confidence interval [CI] 1.10–1.51, p = 0.001; DM OR 1.55 [1.33–1.81], p < 0.001; dyslipidemia OR 1.15 [1.00–1.34], p = 0.053; CKD OR 1.74 [1.43–2.13], p < 0.001; COPD OR 1.41 [1.15–1.72], p < 0.001; history of cardiac disease OR 1.22 [1.05–1.41], p = 0.010, Fig. 2B). Additionally, given the non-linear relationship between age and in-hospital mortality, age-spline adjusted analysis was performed for the association of sex and all comorbidities with in-hospital mortality (Fig. 2C). The effects were attenuated after age-spline adjustment, only leaving sex, DM, CKD, and COPD significantly associated with in-hospital mortality (female OR 0.65 [0.55–0.75], p < 0.001; DM OR 1.47 [1.26–1.72], p < 0.001; CKD OR 1.61 [1.32–1.97], p < 0.001; COPD OR 1.30 [1.07–1.59], p = 0.010, Fig. 2C).
Fig. 2

Associations of age and comorbidities with in-hospital mortality. A) Univariable association of age 70+, sex, and comorbidities with in-hospital mortality; B) Association of all comorbidities after adjustment for age 70+ and sex; C) Association of sex and all comorbidities after age spline adjustment. COPD = chronic obstructive pulmonary disease

Associations of age and comorbidities with in-hospital mortality. A) Univariable association of age 70+, sex, and comorbidities with in-hospital mortality; B) Association of all comorbidities after adjustment for age 70+ and sex; C) Association of sex and all comorbidities after age spline adjustment. COPD = chronic obstructive pulmonary disease Uni- and multivariable (spline-adjusted) analysis of comorbidity count revealed a significant, univariable association with in-hospital mortality (p < 0.001; Additional file 3), which remained significant in the multivariable model with an attenuated effect. In the age-spline multivariable adjusted analysis, the association of the comorbidity count was not significant for a comorbidity count of 1–2 (OR 1.15 [0.9–1.4]) and attenuated for > 2 comorbidity count (OR 1.4 [1.1–1.7]). All individual comorbidities significantly mediated the association between age 70+ and in-hospital mortality (ACME; Fig. 3). However, the proportion of this eff ect was below 6% for all comorbidities, and thereby the increased risk of in-hospital mortality in the elderly was explained mainly by the direct effect (ADE; Fig. 3) of age 70+ within this analysis (Fig. 3). Additionally, a mediation analysis was performed to quantify the mediation effect of a comorbidity count > 2 on the association between age and in-hospital mortality. Although the proportion of this effect was higher than the comorbidities separately, it remained minimal (8%, p < 0.001, Additional file 4).
Fig. 3

Mediation analysis with age ≥ 70 years as independent predictor, the individual comorbidities as mediator and in-hospital mortality as outcome. All comorbidities partly mediated the effect of age on in-hospital mortality (all p-values < 0.001). The mediation effect was 5% (95% CI 2–9%) for hypertension, 3% (95% CI 2–4%) for diabetes mellitus, 3% (95% CI 0.4–6%) for dyslipidemia, 5% (95% CI 3–7%) for chronic kidney disease, 2% (95% CI 1–3%) for COPD, and 5% (95% CI 2–9%) for history of cardiac disease. COPD = chronic obstructive pulmonary disease

Mediation analysis with age ≥ 70 years as independent predictor, the individual comorbidities as mediator and in-hospital mortality as outcome. All comorbidities partly mediated the effect of age on in-hospital mortality (all p-values < 0.001). The mediation effect was 5% (95% CI 2–9%) for hypertension, 3% (95% CI 2–4%) for diabetes mellitus, 3% (95% CI 0.4–6%) for dyslipidemia, 5% (95% CI 3–7%) for chronic kidney disease, 2% (95% CI 1–3%) for COPD, and 5% (95% CI 2–9%) for history of cardiac disease. COPD = chronic obstructive pulmonary disease Age-spline plots showed a steep increase in the predicted risk of in-hospital mortality from 60 years and higher (Fig. 1; analysis stratified by sex and the individual comorbidities is shown in Additional file 5). Correspondingly, in-hospital mortality rates were significantly lower in patients < 60 years when compared to the older patients (age 60+ years, 6% (N = 87) vs 30% (N = 1021), p < 0.001; Additional file 6). All comorbidities also occurred less frequently in this younger patient group (Additional file 6). None of the co-morbidities, except for history of cardiac disease, were significantly associated with in-hospital mortality in univariable analysis in patients < 60 years (hypertension OR 1.31 [0.83–2.06], p = 0.240; DM OR 1.38 [0.82–2.35], p = 0.228; dyslipidemia OR 1.26 [0.76–2.10], p = 0.367; CKD OR 2.33 [0.96–5.66], p = 0.062; COPD OR 0.62 [0.19–2.00], p = 0.421; history of cardiac disease OR 1.90 [1.10–3.27], p = 0.021, Additional file 7). In the total patient population, age 60+ was significantly associated with in-hospital mortality (OR 6.35[5.05–7.98], p < 0.001; Additional file 7A).

Discussion

This study reveals that higher age is the main determinant of COVID-19 related in-hospital mortality in the Netherlands. While pre-existing comorbidities (including hypertension, DM, dyslipidemia, CKD, COPD, and cardiac diseases) are more prevalent in the elderly, their mediation effect on COVID-19 related in-hospital mortality is minimal. Over the last months, studies revealed multiple risk factors independently associated with COVID-19 related (in-hospital) mortality, including higher age, pre-existing co-morbidities, and male sex, which is in line with current findings [9, 10, 22–25]. A recent study of 2273 COVID-19 hospitalized Dutch patients showed that a mortality prediction model using ten clinical features including age, number of home medications, admission blood values urea nitrogen/LDH/albumin, oxygen saturation, blood gas pH and history of chronic cardiac disease, improved discrimination over age-based decision rules only [26]. Nonetheless, no data regarding to which extent age and cardiovascular comorbidities contributed to the mortality risks were provided. We show that the contributing effect of pre-existing comorbidities is minimal relative to age. In the Netherlands, the vast majority (90%) of deceased patients due to COVID-19 is over 70 years of age. The prevalence of comorbidities among hospitalized COVID-19 patients is particularly high, especially in the elderly [7, 8]. The current study included 4806 patients from 45 Dutch - both academic and local - hospitals, accounting for around 40% of all COVID-19 related hospitalizations between January 2020 and July 2020 in the Netherlands [7]. Therefore, this study population adequately represents the total hospitalized population during the first COVID-19 pandemic wave in the Netherlands. The higher prevalence of male COVID patients observed in the current registry and the increased mortality risk of males is in line with previous findings and likely due to a less effective viral control of the immune system in males [24, 27], together with the higher comorbidity rates in males compared to females [24, 28]. The observed association between a medical history of a cardiac disease and in-hospital mortality in the young has been studied and discussed before by current consortium, which is mainly driven by the presence of severe (NYHA≥3) heart failure [29]. It is important to notice that during the first wave of COVID-19, the median age of people referred to the ICU department decreased when the total number of patients referred to the ICU department increased [30]. Younger (< 70+) patients were possibly  more likely to be referred to the ICU department due to bed shortages. However, the percentage of patients aged 70+ in the COVID-19 related  mortality group in the current study (76%) is lower than the overall percentage of subjects aged 70+ of the COVID-19 related deaths in the Netherlands in 2020 (90%) [31]. This likely results from fewer referrals of elderly patients to the hospitals (possibly even independent of the presence of comorbidities) due to the overwhelming stress on hospitals during the first COVID-19 wave. Nonetheless, even in the group aged < 60 years - in whom likely no or limited referral “restrictions” were present - the effect of pre-existing comorbidities on mortality was limited in the current study, indicating that age as such is likely the main driver of COVID-19 related in-hospital mortality. Our study revealed that pre-existing co-morbidities, highly prevalent in the elderly, contributed minimally to in-hospital mortality when compared to age. Moreover, the contribution of the comorbidities to outcome in patients aged < 60 years was limited to a history of cardiac disease without any significant association for DM, CKD, and COPD. As a result, the present study stresses the need for primary preventive efforts to protect the elderly (males) from an infection with SARS-CoV-19.

Limitations

There are some study limitations that need to be addressed, including its retrospective design. Additionally, data concerning the patients’ frailty and the reasons for not referring patients to the hospital or the ICU, were not collected within this registry. To which extent the lower hospital and ICU referral rate of the elderly and frailty contributed to the in-hospital mortality rate could therefore not be assessed and requires further research. Such research could help to better understand the association of higher age and in-hospital mortality beyond the comorbidities and might guide decision making on treatment, counselling and admission to high care facilities in the future.

Conclusion

Age is the main determinant of COVID-19 related in-hospital mortality, which is negligibly mediated by pre-existing comorbidities in the Netherlands. Additional file 1. Supplemental methods. Additional file 2. Clinical characteristics of males and females. Additional file 3. Univariable, and Multivariable and Age cubic Spline adjusted association of Age, Gender, and comorbidity count with in-hospital mortality. Additional file 4. Mediation analysis with Age ≥ 70 as independent predictor, multi-comorbidity (> 2 comorbidities) as mediator and in-hospital mortality as outcome. Additional file 5. Age-spline adjusted associations with predicted in-hospital mortality, stratified for: A) sex; B) number of comorbidities; C) hypertension; D) diabetes mellitus; E) dyslipidemia; F) chronic kidney disease; G) chronic obstructive pulmonary disease (COPD); H) cardiac disease. Additional file 6. Clinical characteristics of patients below and ≥ 60 years of age. Additional file 7. A) Univariable association of Age 60+ with in-hospital mortality in the total cohort B) Univariable association of sex and comorbidities with in-hospital mortality in patients younger than 60 years.
  22 in total

1.  Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries.

Authors: 
Journal:  Eur Heart J       Date:  2022-03-14       Impact factor: 29.983

2.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.

Authors:  Chaomin Wu; Xiaoyan Chen; Yanping Cai; Jia'an Xia; Xing Zhou; Sha Xu; Hanping Huang; Li Zhang; Xia Zhou; Chunling Du; Yuye Zhang; Juan Song; Sijiao Wang; Yencheng Chao; Zeyong Yang; Jie Xu; Xin Zhou; Dechang Chen; Weining Xiong; Lei Xu; Feng Zhou; Jinjun Jiang; Chunxue Bai; Junhua Zheng; Yuanlin Song
Journal:  JAMA Intern Med       Date:  2020-07-01       Impact factor: 21.873

3.  Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy.

Authors:  Giacomo Grasselli; Massimiliano Greco; Alberto Zanella; Giovanni Albano; Massimo Antonelli; Giacomo Bellani; Ezio Bonanomi; Luca Cabrini; Eleonora Carlesso; Gianpaolo Castelli; Sergio Cattaneo; Danilo Cereda; Sergio Colombo; Antonio Coluccello; Giuseppe Crescini; Andrea Forastieri Molinari; Giuseppe Foti; Roberto Fumagalli; Giorgio Antonio Iotti; Thomas Langer; Nicola Latronico; Ferdinando Luca Lorini; Francesco Mojoli; Giuseppe Natalini; Carla Maria Pessina; Vito Marco Ranieri; Roberto Rech; Luigia Scudeller; Antonio Rosano; Enrico Storti; B Taylor Thompson; Marcello Tirani; Pier Giorgio Villani; Antonio Pesenti; Maurizio Cecconi
Journal:  JAMA Intern Med       Date:  2020-10-01       Impact factor: 21.873

4.  Response to "Early Hydroxychloroquine but not Chloroquine use reduces ICU admission in COVID-19 patients".

Authors:  Marijke Linschoten; Linda Nab; Iwan C C van der Horst; Robert Tieleman; Folkert W Asselbergs
Journal:  Int J Infect Dis       Date:  2020-12-09       Impact factor: 3.623

5.  Predictors of In-Hospital Mortality in Older Patients With COVID-19: The COVIDAge Study.

Authors:  Aline Mendes; Christine Serratrice; François R Herrmann; Laurence Genton; Samuel Périvier; Max Scheffler; Thomas Fassier; Philippe Huber; Marie-Claire Jacques; Virginie Prendki; Xavier Roux; Katharine Di Silvestro; Véronique Trombert; Stephan Harbarth; Gabriel Gold; Christophe E Graf; Dina Zekry
Journal:  J Am Med Dir Assoc       Date:  2020-09-15       Impact factor: 4.669

6.  The "sex gap" in COVID-19 trials: a scoping review.

Authors:  Veronique M M M Schiffer; Emma B N J Janssen; Bas C T van Bussel; Laura L M Jorissen; Jeanette Tas; Jan-Willem E M Sels; Dennis C J J Bergmans; Trang H T Dinh; Sander M J van Kuijk; Anisa Hana; Jannet Mehagnoul-Schipper; Clarissa I E Scheeren; Dieter Mesotten; Bjorn Stessel; Gernot Marx; Arnoud W J van T Hof; Marc E A Spaanderman; Walther N K A van Mook; Iwan C C van der Horst; Chahinda Ghossein-Doha
Journal:  EClinicalMedicine       Date:  2020-11-30

7.  Predicting mortality of individual patients with COVID-19: a multicentre Dutch cohort.

Authors:  Marcel J H Aries; Martijn Beudel; Maarten C Ottenhoff; Lucas A Ramos; Wouter Potters; Marcus L F Janssen; Deborah Hubers; Shi Hu; Egill A Fridgeirsson; Dan Piña-Fuentes; Rajat Thomas; Iwan C C van der Horst; Christian Herff; Pieter Kubben; Paul W G Elbers; Henk A Marquering; Max Welling; Suat Simsek; Martijn D de Kruif; Tom Dormans; Lucas M Fleuren; Michiel Schinkel; Peter G Noordzij; Joop P van den Bergh; Caroline E Wyers; David T B Buis; W Joost Wiersinga; Ella H C van den Hout; Auke C Reidinga; Daisy Rusch; Kim C E Sigaloff; Renee A Douma; Lianne de Haan; Niels C Gritters van den Oever; Roger J M W Rennenberg; Guido A van Wingen
Journal:  BMJ Open       Date:  2021-07-19       Impact factor: 2.692

8.  Combination of RT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak.

Authors:  Yishan Wang; Hanyujie Kang; Xuefeng Liu; Zhaohui Tong
Journal:  J Med Virol       Date:  2020-03-11       Impact factor: 2.327

9.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

10.  Factors associated with COVID-19-related death using OpenSAFELY.

Authors:  Elizabeth J Williamson; Alex J Walker; Krishnan Bhaskaran; Seb Bacon; Chris Bates; Caroline E Morton; Helen J Curtis; Amir Mehrkar; David Evans; Peter Inglesby; Jonathan Cockburn; Helen I McDonald; Brian MacKenna; Laurie Tomlinson; Ian J Douglas; Christopher T Rentsch; Rohini Mathur; Angel Y S Wong; Richard Grieve; David Harrison; Harriet Forbes; Anna Schultze; Richard Croker; John Parry; Frank Hester; Sam Harper; Rafael Perera; Stephen J W Evans; Liam Smeeth; Ben Goldacre
Journal:  Nature       Date:  2020-07-08       Impact factor: 49.962

View more
  5 in total

Review 1.  Management of Hematologic Malignancies in the Era of COVID-19 Pandemic: Pathogenetic Mechanisms, Impact of Obesity, Perspectives, and Challenges.

Authors:  Dimitrios Tsilingiris; Narjes Nasiri-Ansari; Nikolaos Spyrou; Faidon Magkos; Maria Dalamaga
Journal:  Cancers (Basel)       Date:  2022-05-19       Impact factor: 6.575

Review 2.  Acute Coronary Syndrome in the COVID-19 Era-Differences and Dilemmas Compared to the Pre-COVID-19 Era.

Authors:  Ratko Lasica; Lazar Djukanovic; Igor Mrdovic; Lidija Savic; Arsen Ristic; Marija Zdravkovic; Dragan Simic; Gordana Krljanac; Dejana Popovic; Dejan Simeunovic; Dubravka Rajic; Milika Asanin
Journal:  J Clin Med       Date:  2022-05-27       Impact factor: 4.964

3.  Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease.

Authors:  Devendra Bansal; Jazeel Abdulmajeed; Maha H M A Al-Shamali; Soha S A Albayat; Sayed M Himatt; Farhan S Cyprian; Tawanda Chivese; Jesha M A Mundodan; Hayat S Khogali; Rekayahouda Baaboura; Anvar H Kaleeckal; Mujeeb C Kandy; Ali Nizar Latif; Mohamed Ghaith Al-Kuwari; Hamad Eid Al-Romaihi; Abdullatif Al Khal; Roberto Bertollini; Mohamed Hamad Al-Thani; Elmobashar Farag; Suhail A R Doi
Journal:  Vaccines (Basel)       Date:  2022-06-28

4.  Race, ethnicity, and utilization of outpatient rehabilitation for treatment of post COVID-19 condition.

Authors:  Claudia B Hentschel; Benjamin A Abramoff; Timothy R Dillingham; Liliana E Pezzin
Journal:  PM R       Date:  2022-07-05       Impact factor: 2.218

5.  Oxidative Stress Biomarkers and Their Association with Mortality among Patients Infected with SARS-CoV-2 in Mexico.

Authors:  Azalia Avila-Nava; Alfredo Geovanny Pech-Aguilar; Roberto Lugo; Isabel Medina-Vera; Martha Guevara-Cruz; Ana Ligia Gutiérrez-Solis
Journal:  Oxid Med Cell Longev       Date:  2022-06-17       Impact factor: 7.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.